Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41541-021-00292-w http://scihub22266oqcxt.onion/10.1038/s41541-021-00292-w 33619260!7900244!33619260     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       NPJ+Vaccines 2021 ; 6 (1): 28 Nephropedia Template TP {{tp|p=33619260|t=2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates |pdf=|usr=}}{{33619260}} gab.com Text SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates JO: NPJ Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=33619260 #FOAvip The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 deaths. Hence, laboratories worldwide are developing an effective vaccine against this disease, which will be essential to reduce morbidity and mortality. Currently, there more than 64 vaccine candidates, most of them aiming to induce neutralizing antibodies against the spike protein (S). These antibodies will prevent uptake through the human ACE-2 receptor, thereby limiting viral entrance. Different vaccine platforms are being used for vaccine development, each one presenting several advantages and disadvantages. Thus far, thirteen vaccine candidates are being tested in Phase 3 clinical trials; therefore, it is closer to receiving approval or authorization for large-scale immunizations. Twit Text FOAVip SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates ????NPJ Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=33619260 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33619260 #FOAvip English Wikipedia <ref>{{Cite pmid|33619260}}</ref> SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates #MMPMID33619260 Kyriakidis NC; Lopez-Cortes A; Gonzalez EV; Grimaldos AB; Prado EO NPJ Vaccines 2021[Feb]; 6 (1): 28 PMID33619260show ga The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 deaths. Hence, laboratories worldwide are developing an effective vaccine against this disease, which will be essential to reduce morbidity and mortality. Currently, there more than 64 vaccine candidates, most of them aiming to induce neutralizing antibodies against the spike protein (S). These antibodies will prevent uptake through the human ACE-2 receptor, thereby limiting viral entrance. Different vaccine platforms are being used for vaccine development, each one presenting several advantages and disadvantages. Thus far, thirteen vaccine candidates are being tested in Phase 3 clinical trials; therefore, it is closer to receiving approval or authorization for large-scale immunizations. äSARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 cand(epmc).pdf DeepDyve Pubget Overpricing